Just take a look at ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), which is up 75%, over three years, soundly beating the market return of 55% (not including dividends). However, more recent returns haven ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non ...

BofA Securities analysts on Wednesday lifted ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s price target to $23 from $18, while ...

Macquarie described Neuren Pharmaceuticals shares as a standout in the biotech industry and set a price target of $18.60 on ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the company appointed Catherine Owen Adams as CEO. What Happened: Acadia ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed ...